Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatologic Agents | 5 | 2015 | 32 | 1.220 |
Why?
|
| Pyoderma Gangrenosum | 3 | 2011 | 7 | 0.850 |
Why?
|
| Drug Hypersensitivity Syndrome | 1 | 2021 | 1 | 0.810 |
Why?
|
| Vancomycin | 1 | 2021 | 60 | 0.780 |
Why?
|
| Psoriasis | 4 | 2008 | 46 | 0.770 |
Why?
|
| Calciphylaxis | 2 | 2015 | 7 | 0.620 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 786 | 0.610 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2015 | 626 | 0.610 |
Why?
|
| Acute Generalized Exanthematous Pustulosis | 1 | 2017 | 1 | 0.580 |
Why?
|
| Mesalamine | 1 | 2017 | 6 | 0.570 |
Why?
|
| Colitis, Ulcerative | 1 | 2017 | 53 | 0.550 |
Why?
|
| Drug Labeling | 1 | 2015 | 32 | 0.510 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 1026 | 0.510 |
Why?
|
| Blood Vessels | 1 | 2015 | 102 | 0.500 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 240 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 4 | 2015 | 511 | 0.480 |
Why?
|
| Radiography | 1 | 2015 | 572 | 0.470 |
Why?
|
| Skin | 2 | 2015 | 451 | 0.430 |
Why?
|
| Leukemoid Reaction | 1 | 2010 | 2 | 0.360 |
Why?
|
| Immunologic Factors | 2 | 2008 | 87 | 0.310 |
Why?
|
| Gynecomastia | 1 | 2005 | 1 | 0.260 |
Why?
|
| Sertoli Cell Tumor | 1 | 2005 | 1 | 0.260 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2005 | 3 | 0.260 |
Why?
|
| Testicular Neoplasms | 1 | 2005 | 27 | 0.260 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 66 | 0.220 |
Why?
|
| Humans | 20 | 2021 | 68618 | 0.210 |
Why?
|
| Skin Diseases | 1 | 2003 | 122 | 0.200 |
Why?
|
| Purpura Fulminans | 1 | 2021 | 2 | 0.200 |
Why?
|
| Splenic Diseases | 1 | 2021 | 10 | 0.200 |
Why?
|
| Biopsy | 4 | 2017 | 540 | 0.200 |
Why?
|
| Purpura | 1 | 2021 | 7 | 0.200 |
Why?
|
| Drug Users | 1 | 2021 | 10 | 0.200 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 30 | 0.200 |
Why?
|
| Middle Aged | 8 | 2021 | 21147 | 0.180 |
Why?
|
| Aged | 5 | 2017 | 14862 | 0.160 |
Why?
|
| Dermatology | 2 | 2015 | 75 | 0.160 |
Why?
|
| Female | 10 | 2021 | 38074 | 0.150 |
Why?
|
| Celiac Disease | 1 | 2017 | 17 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 39 | 0.140 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 63 | 0.140 |
Why?
|
| Infliximab | 3 | 2009 | 16 | 0.140 |
Why?
|
| Gentian Violet | 1 | 2016 | 6 | 0.140 |
Why?
|
| Anemia | 1 | 2017 | 104 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2016 | 47 | 0.140 |
Why?
|
| Epidermis | 1 | 2016 | 42 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2016 | 144 | 0.130 |
Why?
|
| Coloring Agents | 1 | 2016 | 66 | 0.130 |
Why?
|
| Male | 9 | 2017 | 37321 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2015 | 21 | 0.130 |
Why?
|
| Medical Errors | 1 | 2016 | 80 | 0.130 |
Why?
|
| Vitiligo | 1 | 2015 | 12 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 131 | 0.120 |
Why?
|
| Comorbidity | 2 | 2011 | 1426 | 0.120 |
Why?
|
| Lasers, Dye | 1 | 2014 | 4 | 0.120 |
Why?
|
| Lasers, Solid-State | 1 | 2014 | 8 | 0.120 |
Why?
|
| Granuloma, Pyogenic | 1 | 2014 | 5 | 0.120 |
Why?
|
| Scalp Dermatoses | 1 | 2014 | 13 | 0.120 |
Why?
|
| Laser Therapy | 1 | 2014 | 54 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2010 | 1851 | 0.110 |
Why?
|
| Patient Safety | 1 | 2015 | 202 | 0.110 |
Why?
|
| Retinoids | 2 | 2005 | 122 | 0.110 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 191 | 0.110 |
Why?
|
| Mammography | 1 | 2015 | 310 | 0.110 |
Why?
|
| Massachusetts | 1 | 2011 | 28 | 0.100 |
Why?
|
| Skin Diseases, Vascular | 1 | 2011 | 3 | 0.100 |
Why?
|
| Adult | 5 | 2017 | 21403 | 0.090 |
Why?
|
| Debridement | 1 | 2010 | 55 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2010 | 121 | 0.090 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2009 | 1 | 0.080 |
Why?
|
| Leg Dermatoses | 1 | 2009 | 6 | 0.080 |
Why?
|
| Ultraviolet Therapy | 1 | 2008 | 9 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2014 | 186 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 567 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 234 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 376 | 0.070 |
Why?
|
| United States | 2 | 2017 | 7367 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 848 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2324 | 0.060 |
Why?
|
| Arthritis, Psoriatic | 1 | 2005 | 3 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1745 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 4848 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 41 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 529 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2017 | 7277 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 3259 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2003 | 143 | 0.050 |
Why?
|
| Young Adult | 1 | 2011 | 5717 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 931 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2003 | 753 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 334 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 951 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2004 | 2007 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2017 | 33 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2010 | 7029 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2017 | 83 | 0.040 |
Why?
|
| Fixatives | 1 | 2016 | 24 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2016 | 48 | 0.030 |
Why?
|
| Bone Density | 1 | 2017 | 159 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 64 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 100 | 0.030 |
Why?
|
| Melanocytes | 1 | 2015 | 23 | 0.030 |
Why?
|
| Visual Perception | 1 | 2016 | 124 | 0.030 |
Why?
|
| Child | 1 | 2005 | 6405 | 0.030 |
Why?
|
| Timolol | 1 | 2014 | 10 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 2014 | 14 | 0.030 |
Why?
|
| Triamcinolone Acetonide | 1 | 2014 | 10 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 56 | 0.030 |
Why?
|
| Forecasting | 1 | 2015 | 277 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 129 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2016 | 322 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 1465 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 649 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 1342 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 1038 | 0.020 |
Why?
|
| Thiosulfates | 1 | 2011 | 1 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 597 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2011 | 47 | 0.020 |
Why?
|
| Parathyroidectomy | 1 | 2011 | 45 | 0.020 |
Why?
|
| Diphosphonates | 1 | 2011 | 39 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 948 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2077 | 0.020 |
Why?
|
| Leg | 1 | 2010 | 191 | 0.020 |
Why?
|
| Antioxidants | 1 | 2011 | 304 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 219 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1174 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1040 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1738 | 0.010 |
Why?
|